Arcturus Therapeutics (NASDAQ:ARCT) Announces Quarterly Earnings Results, Beats Estimates By $1.08 EPS
Arcturus Therapeutics (NASDAQ:ARCT) Announces Quarterly Earnings Results, Beats Estimates By $1.08 EPS
Arcturus Therapeutics (NASDAQ:ARCT – Get Rating) released its quarterly earnings results on Tuesday. The biotechnology company reported ($0.82) EPS for the quarter, beating analysts' consensus estimates of ($1.90) by $1.08, Fidelity Earnings reports. Arcturus Therapeutics had a negative return on equity of 81.21% and a negative net margin of 1,282.62%. During the same period last year, the firm posted ($2.07) EPS.
Arcturus Treateutics(納斯達克:ARCT-GET評級)週二發佈了季度收益業績。富達收益報告顯示,這家生物技術公司本季度每股收益為0.82美元,比分析師普遍預期的1.90美元高出1.08美元。Arcturus治療公司的淨資產回報率為負81.21%,淨利潤率為負1282.62%。去年同期,該公司公佈的每股收益為2.07美元。
Arcturus Therapeutics Stock Down 4.1 %
Arcturus治療公司股價下跌4.1%
Shares of ARCT traded down $0.75 on Wednesday, reaching $17.48. The company's stock had a trading volume of 678,823 shares, compared to its average volume of 603,511. Arcturus Therapeutics has a twelve month low of $11.70 and a twelve month high of $58.45. The stock has a market capitalization of $461.80 million, a PE ratio of -2.32 and a beta of 2.71. The company has a current ratio of 3.05, a quick ratio of 3.05 and a debt-to-equity ratio of 0.21. The firm has a fifty day moving average of $17.11 and a 200-day moving average of $20.72.
週三,ARCT的股價下跌了0.75美元,達到17.48美元。該公司股票的成交量為678,823股,而其平均成交量為603,511股。Arcturus Treeutics的12個月低點為11.70美元,12個月高位為58.45美元。該股市值為4.618億美元,市盈率為-2.32,貝塔係數為2.71。該公司的流動比率為3.05,速動比率為3.05,債務權益比率為0.21。該公司的50日移動均線切入位為17.11美元,200日移動均線切入位為20.72美元。
Wall Street Analysts Forecast Growth
華爾街分析師預測經濟增長
A number of analysts have weighed in on the stock. The Goldman Sachs Group decreased their target price on shares of Arcturus Therapeutics from $14.00 to $8.00 and set a "sell" rating for the company in a research report on Tuesday, May 24th. Raymond James downgraded Arcturus Therapeutics from a "market perform" rating to an "underperform" rating in a research note on Wednesday. Barclays reduced their price objective on shares of Arcturus Therapeutics from $17.00 to $16.00 and set an "underweight" rating for the company in a research report on Wednesday. Wells Fargo & Company dropped their target price on shares of Arcturus Therapeutics from $105.00 to $98.00 and set an "overweight" rating on the stock in a research report on Wednesday. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Arcturus Therapeutics in a report on Monday, May 9th. Four research analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Hold" and an average target price of $38.75.
許多分析師都加入了對該股的看法。高盛夫婦將Arcturus治療公司的股票目標價從14.00美元下調至8.00美元,並在5月24日(星期二)的一份研究報告中為該公司設定了“賣出”評級。雷蒙德·詹姆斯在週三的一份研究報告中將Arcturus治療公司的評級從“市場表現”下調至“表現不佳”。巴克萊將Arcturus治療公司股票的目標價從17.00美元下調至16.00美元,並在週三的一份研究報告中為該公司設定了“減持”評級。富國銀行(Wells Fargo&Company)週三在一份研究報告中將Arcturus治療公司股票的目標價從105.00美元下調至98.00美元,並對該股設定了“增持”評級。最後,坎託·菲茨傑拉德在5月9日星期一的一份報告中重申了對Arcturus治療公司股票的“增持”評級。四名研究分析師對該股的評級為賣出,兩名分析師給予持有評級,兩名分析師給予該公司買入評級。據MarketBeat.com,該公司平均評級為持有,平均目標價為38.75美元。
Hedge Funds Weigh In On Arcturus Therapeutics
對衝基金入股Arcturus Treeutics
Arcturus Therapeutics Company Profile
Arcturus治療公司簡介
(Get Rating)
(獲取評級)
Arcturus Therapeutics Holdings Inc, an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU.
Arcturus治療控股公司是一家RNA藥物公司,專注於在美國開發針對傳染病、肝臟和呼吸道罕見疾病的疫苗。該公司的開發計劃包括針對鳥氨酸轉氨酶(OTC)缺乏症的LUNAR-OTC開發計劃,以及針對囊性纖維化跨膜傳導調節因子(CFTR)基因突變導致的囊性纖維化肺部疾病的LUNAR-CF計劃,以及包括LUNAR-COV19和LUNAR-Flu在內的疫苗計劃。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Arcturus Therapeutics (ARCT)
- The How And Why of Investing in Oil Stocks
- The How and Why of Investing in Gold Stocks
- Workhorse Group Is Ready To Get Back On The Horse
- A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
- Are 3M, Honeywell, GE Buys After Quarterly Reports?
- 免費獲取StockNews.com關於Arcturus治療(ARCT)的研究報告
- 投資石油股票的方式和原因
- 投資黃金股票的方式和原因
- 工作馬集團準備重返賽馬
- DraftKings,Inc.的圓底開始逆轉
- 3M、霍尼韋爾、通用電氣在季度報告後收購嗎?
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Arcturus治療日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Arcturus治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。